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Family
History of
CAD
(N=1059)
No Family
History of CAD
(N=2542)
Relative
Risk
[95% CI]
p
value
30-day event
MACE 48 (4.5%) 151 (6.0%) 0.76
[0.55,1.05]
0.09
Death 19 (1.8%) 75 (3.0%) 0.60
[0.36,1.00]
0.046
Cardiac 17 (1.6%) 68 (2.7%) 0.60
[0.35,1.01]
0.05
Reinfarction 15 (1.4%) 51 (2.0%) 0.70
[0.39,1.24]
0.22
Ischemia-driven TVR 26 (2.5%) 59 (2.3%) 1.05
[0.66,1.67]
0.82
Ischemia-driven TLR 26 (2.5%) 53 (2.1%) 1.17
[0.73,1.88]
0.50
Deﬁnite or probable
stent thrombosis
20 (2.1%) 56 (2.5%) 0.84
[0.50,1.39]
0.49
3-year event
MACE 210 (20.6%) 547 (22.5%) 0.90
[0.77,1.05]
0.18
Death 49 (4.8%) 188 (7.7%) 0.61
[0.45,0.84]
0.002
Cardiac 27 (2.6%) 112 (4.6%) 0.57
[0.37,0.87]
0.008
Reinfarction 67 (6.7%) 173 (7.4%) 0.90
[0.68,1.20]
0.48
Ischemia-driven TVR 140 (14.0%) 320 (13.7%) 1.02
[0.84,1.25]
0.84
Ischemia-driven TLR 107 (10.7%) 257 (11.0%) 0.97
[0.78,1.22]
0.81
Deﬁnite or probable
stent thrombosis
48 (5.2%) 108 (5.0%) 1.03
[0.73,1.45]
0.87
Value are presented as n (%); CAD¼coronary artery disease; MACE¼major adverse cardiac
event; CI¼conﬁdence interval; TVR¼target vessel revascularization; TLR¼target lesion
revascularization.
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Background: Large thrombotic burden is a well-known predictor of no-reﬂow
phenomenon and mortality in ST-elevation myocardial infarction (STEMI). However,
limited data are available on the clinical signiﬁcance of residual thrombus after
thrombectomy. Therefore, we aimed to investigate the effectiveness of manual
thrombectomy in decreasing thrombus burden, and the effect of residual thrombus on
myocardial perfusion after thrombectomy.
Methods: A multicenter, randomized, prospective trial including 479 acute myocar-
dial infarction (MI) patients was conducted to compare the efﬁcacy and safety of the
everolimus- and zotarolimus-eluting stents for coronary lesions. After excluding 197
non-STEMI patients, 283 STEMI patients undergoing primary percutaneous inter-
vention (PCI) were studied. The no-reﬂow phenomenon incidence after primary PCI
was compared between the small thrombus burden (n¼138) and large thrombus
burden (n¼145) groups, deﬁned by a thrombus score of 3. Aspiration thrombectomy
was performed in 71 large thrombus group patients (49%), and the no-reﬂow inci-
dence in this group was compared based on thrombectomy treatment and pre-stenting
residual thrombus. No-reﬂow phenomenon was deﬁned by a ﬁnal TIMI ﬂow grade of
2 or myocardial blush grade of 1.
Results: No-reﬂow phenomenon occurred frequently in the large thrombus burden
patients without thrombectomy, followed by those who underwent thrombectomy, and
the small thrombus burden group (33.8% vs. 18.9% vs. 10.1%, p<0.001). Fifteen
patients with pre-stenting residual thrombus had a higher no-reﬂow incidence thanB78 JACC Vol 62/18/Suppl B j October 2those without visible pre-stenting thrombus (66.7% vs. 15.7%, p<0.001). Multi-
logistic analysis revealed a baseline TIMI ﬂow grade of 1 (odds ratio [OR] 2.929,
conﬁdence interval [CI] 1.064–8.062), Killip class 2 or 3 (OR 2.452, CI 1.100–5.466),
pre-stenting residual thrombus (OR 7.997, CI 2.186–29.253), and distal embolization
(OR 3.859, CI 1.252–11.893) were independent no-reﬂow phenomenon predictors.
Conclusions: Aspiration thrombectomy substantially reduces no-reﬂow phenomenon
incidence in STEMI patients with large thrombus burden. However, residual thrombus
after thrombectomy increases no-reﬂow phenomenon occurrence.
TCT-238
Low Event Rates At Long-term Follow-up In The Randomized Myocardial
Infarction XAMI Trial Comparing First And Second Generation Drug Eluting
Stents
S. H. Hofma1, Pieter C. Smits2, Arnoud van’t Hof3, M. A. Velders4, A. J. van Boven5
1Medical Center Leeuwarden, Leeuwarden, Friesland, 2Maasstad Hospital
Rotterdam, Rotterdam, Netherlands, 3Isala Klinieken, Zwolle, Netherlands, 4Leiden
University Medical Center, Leiden, Netherlands, 5Medisch Centrum Leeuwarden,
Leeuwarden, Netherlands
Background: Despite initial data of efﬁcacy, concerns were raised regarding the risk
of increased very late stent thrombosis (VLST) using ﬁrst generation drug eluting
stents (DES) compared to bare metal stents in patients with ST-elevation acute
myocardial infarction (STEMI). Though second generation DES have shown even
increased efﬁcacy and lower rates of VLST in stable angina patients, no randomized
data was available in STEMI. The XAMI trial (XienceV stent vs Cypher stent in
primary PCI for Acute Myocardial Infarction) is the ﬁrst randomized trial presenting
three year follow-up data of second generation DES in STEMI patients.
Methods: 625 patients (all-comers) treated with primary PCI for STEMI were
randomized 2:1 to everolimus-eluting stents (EES) or sirolimus-eluting stents (SES).
Exclusion criteria were minimal. The primary endpoint was major adverse cardiac
events (MACE), consisting of cardiac death, non-fatal myocardial infarction or any
target vessel revascularization (TVR) at one year. Secondary endpoints included
MACE at 3 years and stent thrombosis rates.
Results: At one year, non-inferiority of the primary endpoint was shown: 4.0% (EES)
versus 7.7% (SES) (p ¼ 0.048), suggesting superiority of the EES. Deﬁnite and/or
probable stent thrombosis rate was low, 1.2% (EES) versus 2.7% (SES) (p¼0.21).
Radial approach was used in over 50 % of patients as was thrombus aspiration. First
medical contact to balloon inﬂation time was a median of only 75 minutes. At three
years, MACE rate was 8.0% (EES) versus 10.5% (SES) (p¼0.30). Cardiac death rate
was low at 2.5% (EES) versus 2.7% (SES) (p¼0.86) as was overall target lesion
revascularization (TLR) rate at 2.3%. Deﬁnite and/or probable stent thrombosis rate
between one and three year was low with 1.1% for EES and only 0.5% for SES.
Conclusions: This contemporary all-comer STEMI trial showed very low cardiac
mortality, TLR and stent thrombosis rates at three year follow-up with both ﬁrst and
second generation DES. With these low event rates no advantage of second generation
DES could be seen.TCT-239
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Background: Primary PCI for STEMI may lead to rapid washout of CK-MB. There is
insufﬁcient information correlating peak CK-MB to infarct size.
Methods: NFUSE-AMI randomized pts with anterior STEMI undergoing bivalirudin
supported primary PCI to intralesion abciximab vs. no abciximab and to manual
thrombus aspiration vs. no aspiration. In 311 pts left ventricular (LV) ejection fraction
(EF) and infarct size (as a percentage of total LV mass) were evaluated by cardiac
magnetic resonance imaging (cMRI) at 30 days and compared to peak CK-MB. Pts
were clinically followed for 1-year.
Results: Median peak CK-MB was 240 IU/L (IQR: 126 to 414) which was strongly
correlated with infarct size evaluated by cMRI (Figure). Pts in the highest peak CK-
MB tertile had signiﬁcantly larger infarct size (32.3% vs. 21.7% vs. 5.7%, p<0.001)
and lower LVEF (41.5% vs. 48.4% vs. 52.1%, p<0.001) than patients in the middle
and lowest tertiles. Peak CK-MB of 200 IU/L predicted both a large infarct size
(>20% of LV mass: sensitivity 94%, AUC 0.86) and LVEF <40% (sensitivity 91%,
AUC 0.78). Furthermore, peak CK-MB was an independent predictor of 1-year7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
